Innovations in Malaria Vaccine Development (IMV)

$37.57M USD

Funder	Department of State
Recipient Organization	PATH
Country	World
Start Date	Aug 05, 2020
End Date	May 23, 2025
Duration	1,752 days
Number of Grantees	50
Roles	Recipient
Data Source	US Foreign Aid
Grant ID	`217048-76`

Grant Description

The goal of USAIDs Malaria Vaccine Development Program (MVDP) is to demonstrate the proof of concept of a vaccine to reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. Target malaria vaccine end characteristics will include at least 75% efficacy and evidence of affordability.

USAID intends to support efforts towards vaccines that have the potential to directly protect recipients against disease caused by P. falciparum such as vaccines that target the pre-erythrocytic (sporozoite and liver stage) and erythrocytic stages of the life cycle.